Abstract
There is limited information on the patient characteristics and outcomes of people with mantle cell lymphoma (MCL), or the treatment strategies adopted to their management in the Australian real-world setting. The purpose of this study was to describe the treatment patterns and outcomes of people with MCL who receive treatment under the Australian Pharmaceutical Benefits Scheme (PBS).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
